Publications by authors named "A Berthe"

Background: Limited research exists on pricing policies from a bibliometric and visualization perspective, and there is a lack of understanding of their typology. This study aims to address these gaps in knowledge and provide a deeper understanding of the research topics and development trends in this field.

Methods: A bibliometric study was conducted on drug pricing approaches in healthcare literature, published between 2000 and June 2023.

View Article and Find Full Text PDF

Deliberate lightening of skin among African women is a complex phenomenon that intersects with cultural identity, health, beauty, and societal influence. The scientific literature has scarcely explored a comprehensive approach by interviewing users of skin lightening products. This article aims to analyze, through a comprehensive approach, the motivations underlying the deliberate lightening of skin among Burkinabe women.

View Article and Find Full Text PDF

Background: Since March 2020, COVID-19 has evolved from a localized outbreak to a global pandemic. We assessed the seroprevalence of COVID-19 in three towns in the Centre Sud region of Burkina Faso.

Methods: A population-based cross-sectional survey was conducted in three middle-sized cities in Burkina Faso's Centre Sud region, from June to July 2021.

View Article and Find Full Text PDF

Ozone (O) is one of the most harmful and widespread air pollutants, affecting crop yield and plant health worldwide. There is evidence that O reduces the major limiting factor of photosynthesis, namely CO mesophyll conductance (g), but there is little quantitative information of O-caused changes in key leaf anatomical traits and their impact on g. We exposed two O-responsive clones of the economically important tree species Populus × canadensis Moench to 120 ppb O for 21 days.

View Article and Find Full Text PDF
Article Synopsis
  • - Lymphedema (LE), a serious condition resulting from lymphatic filariasis, is primarily treated through limb hygiene and local care, with a study exploring doxycycline's potential benefits.
  • - A multicenter trial in Mali tested doxycycline (200 mg/day) against a placebo for 6 weeks in patients with LE stages 1-3, measuring the disease's progression over 24 months.
  • - Results showed no significant difference in LE progression between the doxycycline and placebo groups, but both experienced reduced acute adenolymphangitis attacks; doxycycline was well tolerated but not more effective than hygiene alone.
View Article and Find Full Text PDF